Search company, investor...
CDx Diagnostics company logo

CDx Diagnostics

cdxdiagnostics.com

Founded Year

2010

Stage

Unattributed - II | Alive

Total Raised

$16.04M

Last Raised

$5M | 3 yrs ago

About CDx Diagnostics

CDx Diagnostics specializes in the detection and prevention of cancers of the esophagus, oral cavity, pharynx, and larynx. CDx Diagnostics provides clinicians with tools to enhance their detection of precancerous change through more complete epithelial sampling combined with computer-assisted morphological and molecular laboratory analysis.

Headquarters Location

Two Executive Boulevard Suite 102

Suffern, New York, 10901,

United States

866-363-6239

Missing: CDx Diagnostics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: CDx Diagnostics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing CDx Diagnostics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CDx Diagnostics is included in 6 Expert Collections, including Medical Devices.

M

Medical Devices

8,605 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharma Tech

15,795 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

H

Health Monitoring & Diagnostics

2,909 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

D

Digital Health

13,069 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

H

Health IT

8,264 items

CDx Diagnostics Patents

CDx Diagnostics has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/13/2015

Inflammations, Autoimmune diseases, Gastrointestinal tract disorders, Gastroenterology, Abdominal pain

Application

Application Date

4/13/2015

Grant Date

Title

Related Topics

Inflammations, Autoimmune diseases, Gastrointestinal tract disorders, Gastroenterology, Abdominal pain

Status

Application

Latest CDx Diagnostics News

Avalon Healthcare Solutions’ Client BCBS of South Carolina Adds CDx Diagnostics as In-Network Lab

Jun 14, 2022

June 14, 2022 09:30 AM Eastern Daylight Time SUFFERN, N.Y.--( BUSINESS WIRE )--CDx Diagnostics, Inc. is pleased to announce that it has signed an agreement with laboratory benefits management provider Avalon Healthcare Solutions, Inc. of Tampa, Fla. The agreement means that CDx will be an in-network specialty anatomic pathology laboratory of Avalon client BlueCross BlueShield of South Carolina, and builds on Avalon’s positive medical policy for CDx’s proprietary diagnostic platform, WATS3D. Short for wide-area transepithelial sampling with three-dimensional analysis, WATS3D utilizes enhanced tissue acquisition, 3D imaging with AI-powered analysis, and expert pathologists to reliably detect Barrett’s esophagus (BE) and esophageal dysplasia. Effectively immediately, the agreement makes WATS3D available to the 565,000 members of BCBS of South Carolina with all commercial and Medicare Advantage plans. “At CDx, we’re driven to empower physicians to preempt esophageal cancer and improve patient lives,” said Bill Huffnagle, CEO of CDx Diagnostics. “This new agreement with Avalon brings modern, proven diagnostic technology to more than half a million more members. We will work together to bring this potentially lifesaving technology to additional payors and the members they serve.” WATS3D technology helps clinicians overcome the limitations associated with traditional upper endoscopy screening and surveillance methods, by combining a specially designed brush, unique 3D imaging powered by AI, and a team of trained GI pathologists. In large multicenter clinical studies, WATS3D has been found to significantly increase the detection rate of BE and esophageal dysplasia, both treatable precursors to esophageal cancer, one of the fastest growing and most fatal cancers in the United States. About CDx Diagnostics CDx Diagnostics’ mission of Empowering Physicians with Innovative Technology to Prevent Esophageal Cancer, One Patient at a Time is accomplished through a proprietary diagnostic platform. This combination of technology synthesizes computer imaging, artificial intelligence, molecular biology and three-dimensional cytopathology to detect precancerous changes earlier and more reliably than prior methods. CDx tests require only a few minutes of practice time, are highly cost effective, widely reimbursed, and address a recognized critical gap in the current diagnostic standard of care. Routine clinical use of CDx testing has detected thousands of cancers and precancerous conditions that otherwise would have been missed in time for effective treatment. CDx Diagnostics is a Galen Partners portfolio company. To learn more, visit www.cdxdiagnostics.com . Contacts

CDx Diagnostics Frequently Asked Questions (FAQ)

  • When was CDx Diagnostics founded?

    CDx Diagnostics was founded in 2010.

  • Where is CDx Diagnostics's headquarters?

    CDx Diagnostics's headquarters is located at Two Executive Boulevard, Suffern.

  • What is CDx Diagnostics's latest funding round?

    CDx Diagnostics's latest funding round is Unattributed - II.

  • How much did CDx Diagnostics raise?

    CDx Diagnostics raised a total of $16.04M.

  • Who are the investors of CDx Diagnostics?

    Investors of CDx Diagnostics include Galen Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.